BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bagepally BS, Chaikledkaew U, Gurav YK, Anothaisintawee T, Youngkong S, Chaiyakunapruk N, McEvoy M, Attia J, Thakkinstian A. Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Res Care 2020;8:e001020. [PMID: 32690574 DOI: 10.1136/bmjdrc-2019-001020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Veettil SK, Harris J, Syeed MS, Thakkinstian A, Chaikledkaew U, Witt DM, Chaiyakunapruk N. Incremental net monetary benefit of direct oral anticoagulants for the prevention of venous thromboembolism after total knee or hip replacement: A systematic review and meta-analysis. Thromb Res 2022;216:74-83. [PMID: 35753113 DOI: 10.1016/j.thromres.2022.06.004] [Reference Citation Analysis]
2 Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, Attia J, Thakkinstian A. Meta-analysis of economic evaluation studies: data harmonisation and methodological issues. BMC Health Serv Res 2022;22:202. [PMID: 35168619 DOI: 10.1186/s12913-022-07595-1] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Bagepally BS, Sajith Kumar S, Natarajan M, Sasidharan A. Incremental net benefit of cholecystectomy compared with alternative treatments in people with gallstones or cholecystitis: a systematic review and meta-analysis of cost–utility studies. BMJ Open Gastroenterol 2022;9:e000779. [DOI: 10.1136/bmjgast-2021-000779] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Udayachalerm S, Renouard MG, Anothaisintawee T, Thakkinstian A, Veettil SK, Chaiyakunapruk N. Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence. J Med Econ 2022;25:26-37. [PMID: 34791974 DOI: 10.1080/13696998.2021.2008195] [Reference Citation Analysis]
5 Bagepally BS, Sasidharan A. Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies. Eur J Clin Pharmacol 2021. [PMID: 34708270 DOI: 10.1007/s00228-021-03242-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yang CY, Chen YR, Ou HT, Kuo S. Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review. Cardiovasc Diabetol 2021;20:21. [PMID: 33468131 DOI: 10.1186/s12933-020-01211-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]